Rapid Care

Cancer cannot wait so every moment counts.
Start your cancer treatment plan within 24-48 hours with Rapid Care.

Learn More

Rapid Second Opinions

Exploring a second opinion with one of our Board Certified Oncologists will help you make a more informed decision about your cancer treatment.

Learn More

Non-Surgical CyberKnife Radiosurgery

CyberKnife offers the most advanced and precise radiosurgery treatment for tumors anywhere in the body with no anesthesia and minimal side effects.

More About CyberKnife

Proud Member of Seattle Cancer Care Alliance Network

Bringing together leading research teams and cancer specialists of Fred Hutchinson Cancer Research Center, Seattle Children's, and UW Medicine

Learn More

Summit News

  • dual immunotherapy lung cancer trial Summit First to Offer Exciting New Lung Cancer Dual Immunotherapy Trials
    Summit Cancer Centers | February 7, 2018

    Summit Cancer Centers is First in the Inland Northwest to Obtain a New Generation of Dual Immunotherapy Trials for First Line Metastatic Non-Small Cell Lung Cancer. Immunotherapy has revolutionized the treatment of metastatic non-small cell lung cancer. However, not every patient responds to single agent immunotherapy, either alone or in…
    Read more

  • Pancreatic Cancer Clinical Trial Promising New Pancreatic Cancer Clinical Trial Now at Summit Cancer Centers
    Summit Cancer Centers | January 23, 2018

    Summit Cancer Centers is first in Washington to offer the Phase 3 Clinical Trial of Immunotherapy AM0010 for Metastatic Adenocarcinoma of the Pancreas. “We are proud to offer an immunotherapy trial for advanced adenocarcinoma of the pancreas,” states Dr. Arvind Chaudhry, Director of Research at Summit Cancer Centers. Current treatments…
    Read more

  • New Lymphoma Drug Trial Summit Cancer Centers is First in the Nation to Offer a New Lymphoma Drug Trial
    Summit Cancer Centers | January 4, 2018

    Summit Cancer Centers is first in the nation to offer Duvelisib, a new Lymphoma drug trial for patients with CLL who have experienced relapse on Ibrutinib. FDA approval of Imbruvica (ibrutinib) in February of 2014 revolutionized the treatment and outcome of patients with chronic lymphocytic lymphoma (CLL). Median survival rates of…
    Read more


Choose where you would like to share this post!